Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...
More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...
Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...
Northwestern Medicine scientists have uncovered a key pathway controlling tumor growth in B-cell lymphomas, according to a ...
The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).
Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...
The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...
Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...
Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...
Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...
Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.
The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback